DDInter1435 DDInter1741
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high
Tagraxofusp is a CD123-directed cytotoxin. It is a fusion protein composed of a human interleukin-3 (IL-3) that is genetically fused to the catalytic and translocation domains of truncated diphtheria toxin (DT) produced in _Escherichia coli_.[A253762, A253887, L43702] Tagraxofusp received its first global approval by the FDA on December 21, 2018 as the first FDA-approved treatment for blastic plasmacytoid dendritic cell neoplasm, which is a myeloid malignancy in the dendritic cell lineage. It was also approved by the European Commission on January 7, 2021.
Tagraxofusp {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Exenatide
Tagraxofusp {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Remdesivir
Tagraxofusp {u} may lead to a major life threatening interaction when taken with {v} Mipomersen
Tagraxofusp may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Tagraxofusp may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Tagraxofusp may lead to a major life threatening interaction when taken with Mipomersen